SCHEMBL24285989

SCHEMBL24285989

Nc1nc2ccc(-c3cnc4[nH]ccc4c3Cl)cn2c1C(=O)C1CNC1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 7/20 0.34
▸ CDK4 P11802 5/20 0.34
▸ JAK1 P23458 3/20 0.34
▸ PRKCI P41743 2/20 0.34
▸ PRKCA P17252 1/20 0.34
▸ PRKCE Q02156 1/20 0.34
▸ AXL P30530 1/20 0.32
▸ RPS6KA3 P51812 1/20 0.32
▸ JAK3 P52333 2/20 0.32
▸ CCNC P24863 1/20 0.31
▸ CDK8 P49336 1/20 0.31
▸ CDK19 Q9BWU1 1/20 0.31
▸ ABL1 P00519 3/20 0.31
▸ LRRK2 Q5S007 1/20 0.31
▸ JAK2 O60674 1/20 0.31
▸ TYK2 P29597 1/20 0.31
▸ IKBKB O14920 1/20 0.31
▸ CHUK O15111 1/20 0.31
▸ MGLL Q99685 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29537364 1.00 CDK2 (0.34) CDK2CDK4JAK1PRKCIPRKCA
SCHEMBL24285931 0.93 JAK1 (0.34) CDK2CDK4JAK1PRKCIPRKCA
SCHEMBL29537272 0.93 JAK1 (0.34) CDK2CDK4JAK1PRKCIPRKCA
SCHEMBL29537655 0.89 PRKCA (0.35) JAK1PRKCIPRKCAPRKCERPS6KA3
SCHEMBL24285965 0.89 PRKCA (0.35) JAK1PRKCIPRKCAPRKCERPS6KA3
SCHEMBL24285860 0.87 ABL1 (0.41) ABL1LRRK2
SCHEMBL29537535 0.83 JAK1 (0.36) JAK1PRKCIPRKCAPRKCERPS6KA3
SCHEMBL24285879 0.83 JAK1 (0.36) JAK1PRKCIPRKCAPRKCERPS6KA3
SCHEMBL24285848 0.81 LRRK2 (0.47) CDK2AXLCCNCCDK8ABL1
SCHEMBL29537003 0.81 LRRK2 (0.47) CDK2AXLCCNCCDK8ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4214207-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1st Biotherapeutics, Inc. (KR) 2023-07-26 — — EP claimed
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1ST Biotherapeutics, Inc. (KR) 2022-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds NLRP3, NLRP1, KCNJ2 CDK2 952/4885CDK4 1557/4885JAK1 109/4885
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS NLRP3, NLRP1, KCNJ2 CDK2 952/4885CDK4 1557/4885JAK1 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback